microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1. 2022

Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
The Second Department of General Surgery, Zhuhai People's Hospital, Zhuhai 51900, Guangdong, China.

Cancer stem cells (CSCs) comprise a small population of cells in cancerous tumors and play a critical role in tumor resistance to chemotherapy. miRNAs have been reported to enhance the sensitivity of pancreatic cancer to chemotherapy. However, the underlying molecular mechanism requires better understanding. Cell viability and proliferation were examined with CCK8 assays. Quantitative real-time polymerase chain reaction was executed to assess mRNA expression. StarBase database was used to select the target genes of miRNA, which were further affirmed by dual luciferase assay. Transwell assay was used to analyze cell invasion and migration. We proved that miR-497 could be obviously downregulated in pancreatic cancer tissues and CSCs from Aspc-1 and Bxpc-3 cells. In addition, inhibition of miR-497 evidently accelerated pancreatic CSC gemcitabine resistance, migration and invasion. Moreover, we revealed that nuclear factor kappa B 1 (NFκB1) was prominently upregulated in pancreatic cancer tissues and pancreatic CSCs, and NFκB1 was also identified as a direct target of miR-497. Furthermore, we demonstrated that overexpression of NFκB1 could also notably promote the viability, migration, and invasion of gemcitabine-treated pancreatic CSCs, but this effect could be partially abolished by miR-497 overexpression. Those findings suggest that miR-497 overexpression could suppress gemcitabine resistance and the metastasis of pancreatic CSCs and non-CSCs by directly targeting NFκB1.

UI MeSH Term Description Entries
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000093542 Gemcitabine A deoxycytidine antimetabolite used as an antineoplastic agent. 2',2'-Difluoro-2'-Deoxycytidine,2',2'-Difluorodeoxycytidine,2'-Deoxy-2',2''-Difluorocytidine-5'-O-Monophosphate,2'-Deoxy-2'-Difluorocytidine,Gemcitabine Hydrochloride,Gemcitabine, (D-threo-pentafuranosyl)-Isomer,Gemcitabine, (alpha-D-threo-pentofuranosyl)-Isomer,Gemcitabine, (beta-D-threo-pentafuranosyl)-Isomer,Gemicitabine,2',2'-DFDC,Gemzar,LY 188011,LY-188011,dFdCyd,188011, LY,2' Deoxy 2' Difluorocytidine,2' Deoxy 2',2'' Difluorocytidine 5' O Monophosphate,Hydrochloride, Gemcitabine
D014411 Neoplastic Stem Cells Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS. Cancer Stem Cells,Colony-Forming Units, Neoplastic,Stem Cells, Neoplastic,Tumor Stem Cells,Neoplastic Colony-Forming Units,Tumor Initiating Cells,Cancer Stem Cell,Cell, Cancer Stem,Cell, Neoplastic Stem,Cell, Tumor Initiating,Cell, Tumor Stem,Cells, Cancer Stem,Cells, Neoplastic Stem,Cells, Tumor Initiating,Cells, Tumor Stem,Colony Forming Units, Neoplastic,Colony-Forming Unit, Neoplastic,Initiating Cell, Tumor,Initiating Cells, Tumor,Neoplastic Colony Forming Units,Neoplastic Colony-Forming Unit,Neoplastic Stem Cell,Stem Cell, Cancer,Stem Cell, Neoplastic,Stem Cell, Tumor,Stem Cells, Cancer,Stem Cells, Tumor,Tumor Initiating Cell,Tumor Stem Cell,Unit, Neoplastic Colony-Forming,Units, Neoplastic Colony-Forming
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
November 2017, Molecular medicine reports,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
September 2017, Oncology letters,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
November 2022, Molecular medicine reports,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
March 2016, Oncology reports,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
July 2015, Journal of experimental & clinical cancer research : CR,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
June 2022, Oncology reports,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
January 2023, Anais da Academia Brasileira de Ciencias,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
January 2015, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
December 2017, Molecular medicine reports,
Qiangfeng Yu, and Zhe Xiu, and Yizeng Jian, and Jianyin Zhou, and Xiaopeng Chen, and Xiang Chen, and Chunxiang Chen, and Hongbao Chen, and Sijia Yang, and Libo Yin, and Wenlong Zeng
February 2021, European review for medical and pharmacological sciences,
Copied contents to your clipboard!